安徽医科大学学报Issue(7)：1018-1021,4.
硼替佐米治疗多发性骨髓瘤的疗效和安全性分析
Efficacy and safety of bortezomib in the treatment of patients with multiple myeloma
摘要
Abstract
The clinical features of all 25 multiple myeloma ( MM ) patients who were treated with BDT regimen ( bortezomib and dexamethasone and thalidomide) were recruited. The efficacy and related influence factors and ad-verse drug reactions were retrospectively evaluated. The overall remission(OR) rate was 80. 00%(20/25) and the complete remission (CR) rate was 36. 00% (9/25),very good partial remission (VGPR) and partial remission (PR) rate were 24. 00% (6/25) and 20. 00%(5/25) respectively in MM patients with BDT regimen. The OR rate of relapsing/refractory MM patients was not statistically lower than that of newly-diagnosed MM patients (62. 5% vs 88. 24%,P>0. 05). The OR rate of ISSⅢstage patients was as better as that of ISS I andⅡstage pa-tients(83. 33% vs 76. 92%, P>0. 05). The CR rate of the arm who received many cycle regimens(≥4 cycles) was higher than that of the arm who received 4 cycles regimens(3,2,1 cycles),but there was no statistically signifi-cant difference. The patients with plasma cell leukemia and renal failure were treated with bortezomib based regi-men and achieved PR or above. The main adverse effects were peripheral neuropathy,gastrointestinal symptoms, thrombocytopenia,neutropenia,skin rash,et al. All adverse events were diminished by using routine ways.关键词
多发性骨髓瘤/硼替佐米/疗效/不良反应Key words
multiple myeloma/bortezomib/treatment outcome/adverse reaction分类
医药卫生引用本文复制引用
秦慧,汪延生,丁士华,吴凡,王芝涛,王强生..硼替佐米治疗多发性骨髓瘤的疗效和安全性分析[J].安徽医科大学学报,2014,(7):1018-1021,4.基金项目
安徽省教育厅自然科学基金(编号:KJ2009A78) （编号:KJ2009A78）
